12-week Randomized Study to Compare the Effect of Vildagliptin vs. Glibenclamide Associated to Metformin in Endothelial Function in Patients With Type 2 Diabetes and Hypertension
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Vildagliptin (Primary) ; Glibenclamide
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
Most Recent Events
- 18 Mar 2019 Results presented at the 101st Annual Meeting of the Endocrine Society
- 04 Apr 2017 Primary endpoint has not been met. (Change from baseline in the reactive hyperemia index (RHI) after 12 weeks of vildagliptin x glibenclamide treatment) as per results presented at The 99th Annual Meeting of the Endocrine Society
- 04 Apr 2017 Results presented at The 99th Annual Meeting of the Endocrine Society